{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Yang X"],"funding":["Beijing Youth Program for Outstanding Talents","Beijing Medical Award Foundation Youth Committee of Lung Cancer Crowd-funding Project","Beijing Hospitals Authority Youth Programme","Beijing Municipal Administration of Hospitals Incubating Program"],"pagination":["1107"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8520304"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["21(1)"],"pubmed_abstract":["<h4>Background</h4>EGFR and ALK alternations often contribute to human malignancies, including lung cancer. EGFR and ALK mutations are usually sensitive to EGFR-tyrosine kinase inhibitors (TKIs) and ALK-TKIs. Although generally mutually exclusive, these mutations do co-exist in rare cases. This study investigated the frequencies, clinical characteristics, therapeutic efficacies, and genetic profiles of lung cancer patients with EGFR and ALK co-mutations.<h4>Methods</h4>Patients with concurrent EGFR and ALK mutations were included in this study, which analyzed mutation profiles and treatment histories. SPSS20.0 were used for survival analysis.<h4>Results</h4>Among 271 ALK-positive (ALK-pos) and 2975 EGFR-positive (EGFR-pos) patients in our database, nine (2.6% of ALK-pos and 0.2% of EGFR-po"],"journal":["BMC cancer"],"pubmed_title":["Genetic and treatment profiles of patients with concurrent Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) mutations."],"pmcid":["PMC8520304"],"funding_grant_id":["PX2019038","202001001","QML20191112","2018000021469G262","PX2020044"],"pubmed_authors":["Yang X","Zhuo M","Xia X","Zhang M","Zhong J","Yu Z","Chen R","Zhao J"],"additional_accession":[]},"is_claimable":false,"name":"Genetic and treatment profiles of patients with concurrent Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) mutations.","description":"<h4>Background</h4>EGFR and ALK alternations often contribute to human malignancies, including lung cancer. EGFR and ALK mutations are usually sensitive to EGFR-tyrosine kinase inhibitors (TKIs) and ALK-TKIs. Although generally mutually exclusive, these mutations do co-exist in rare cases. This study investigated the frequencies, clinical characteristics, therapeutic efficacies, and genetic profiles of lung cancer patients with EGFR and ALK co-mutations.<h4>Methods</h4>Patients with concurrent EGFR and ALK mutations were included in this study, which analyzed mutation profiles and treatment histories. SPSS20.0 were used for survival analysis.<h4>Results</h4>Among 271 ALK-positive (ALK-pos) and 2975 EGFR-positive (EGFR-pos) patients in our database, nine (2.6% of ALK-pos and 0.2% of EGFR-po","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Oct","modification":"2025-04-22T11:27:11.662Z","creation":"2025-04-05T23:58:42.005Z"},"accession":"S-EPMC8520304","cross_references":{"pubmed":["34654390"],"doi":["10.1186/s12885-021-08824-2"]}}